Abraham, Jean E. http://orcid.org/0000-0003-0688-4807
Pinilla, Karen http://orcid.org/0000-0002-2723-0805
Dayimu, Alimu
Grybowicz, Louise
Demiris, Nikolaos
Harvey, Caron
Drewett, Lynsey M.
Lucey, Rebecca http://orcid.org/0000-0002-6226-447X
Fulton, Alexander
Roberts, Anne N.
Worley, Joanna R.
Chhabra, Anita http://orcid.org/0000-0002-9899-8010
Qian, Wendi http://orcid.org/0000-0002-4238-3471
Vallier, Anne-Laure
Hardy, Richard M.
Chan, Steve
Hickish, Tamas
Tripathi, Devashish
Venkitaraman, Ramachandran
Persic, Mojca
Aslam, Shahzeena
Glassman, Daniel
Raj, Sanjay
Borley, Annabel
Braybrooke, Jeremy P.
Sutherland, Stephanie
Staples, Emma
Scott, Lucy C.
Davies, Mark
Palmer, Cheryl A.
Moody, Margaret
Churn, Mark J.
Newby, Jacqueline C.
Mukesh, Mukesh B.
Chakrabarti, Amitabha
Roylance, Rebecca R.
Schouten, Philip C.
Levitt, Nicola C.
McAdam, Karen
Armstrong, Anne C.
Copson, Ellen R.
McMurtry, Emma
Tischkowitz, Marc http://orcid.org/0000-0002-7880-0628
Provenzano, Elena
Earl, Helena M.
Article History
Received: 6 February 2024
Accepted: 4 April 2024
First Online: 8 April 2024
Competing interests
: The authors declare competing financial interests in the form of research grants and honoraria for lectures. The funders of the research grants and honoraria had no role in the study design, data collection, analysis, interpretation or writing of the manuscript. J.E.A. reports honoraria, conference attendance travel support and a grant from AstraZeneca; and honoraria from Esai and Pfizer for lectures. M.M. reports shares in AstraZeneca. M.B.M. reports advisory board membership of Roche, Pfizer, MSD, Daiichi Sankyo, Gilead, AstraZeneca, Novartis, the Menarini Group, Genomic Health (Precision Medicine) and Seagen; speaker honoraria from Roche, BMS, Seagen, Pfizer, Daiichi Sankyo, AstraZeneca, Lilly, MSD, Genomic Health (Precision Medicine), Eisai and Novartis; and meeting expenses from Roche, Eli Lilly, Novartis and MSD. R.R.R. reports honoraria from Daiichi Sankyo, AstraZeneca, Novartis and Pfizer; membership of advisory boards for Daiichi Sankyo, Eli Lilly, Pfizer and AstraZeneca; and travel and conference attendance from BMS, Pfizer and Roche. P.C.S. reports that their partner is employed by AstraZeneca. N.C.L. reports shares in AstraZeneca. A.C.A. reports research funding paid to their institution from AstraZeneca; conference fees and travel expenses from Roche and Novartis; conference fees from MSD; membership of Roche and AstraZeneca advisory boards; and a grant for an educational project from Gilead. E.R.C. reports honoraria from AstraZeneca, Eli Lilly, Novartis, Pfizer and Roche; membership of advisory boards for AstraZeneca, Eli Lilly, Pfizer, Menarini Stemline UK and Novartis; consultancy for Pfizer; conference fees, travel and accommodation from Roche and Novartis; an educational grant from Daiichi Sankyo; and research funding and support from SECA and AstraZeneca. E.P. reports honoraria from Roche, Novartis and AstraZeneca. The remaining authors declare no competing interests.